Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib - Aptose Biosciences ( NASDAQ:APTO )

3 weeks ago

SAN DIEGO and TORONTO, Aug. 30, 2024 ( GLOBE NEWSWIRE ) -- Aptose Biosciences Inc. ( "Aptose" or the "Company" ) APTOAPS, a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia ( ...

Ticker	Sentiment	Impact
APTO	Neutral	17 %